Referencias

1. American Cancer Society. What is Lung Cancer? Accessed January 2021. https://www.cancer.org/cancer/lungcancer/about/what-is.html
2. World Health Organization. Cancer Fact Sheet. January 2021. https://www.who.int/news-room/fact-sheets/detail/cancer
3. Latin America and the Caribbean – Global Cancer Observatory. Globocan 2020. Acceso: 18 de agosto del 2021: https://gco.iarc.fr/today/data/factsheets/populations/904-latin-america-...

 
Referencias

4. Feng Y, et al. Exploratory analysis of introducing next-generation sequencing-based method to treatment- naive lung cancer patients. J Thorac Dis. 2018;10:5904-5912.
5. Pinherio A, et al. Using Metaphors to Explain Molecular Testing to Cancer Patients. Oncologist. 2017 Apr;22(4):445-449. doi: 10.1634/theoncologist.2016-0270. Epub 2017 Feb 20.
6. Jordan E, et al. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discov. 7(6); 596–609.
7. Zhang Y, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016 Nov 29; 7(48): 78985–78993.
8. Raez LE, Cardona AF, Santos ES, Catoe H, Rolfo C, Lopes G, Barrios C, Mas LA, Vallejos C, Zatarain-Barrón ZL, Caglevic C, Arrieta O. La carga del cáncer de pulmón en América Latina y los desafíos en el acceso al perfil genómico, la inmunoterapia y los tratamientos dirigidos. Cáncer de pulmón. 2018 mayo; 119:7-13. doi: 10.1016/j.lungcan. 2018.02.014. Epub 2018 mar 2. PMID: 29656755.
9. Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Sig Transduct Target Ther. 4, 5 (2019). 10. Riess JW, Gandar DR, Frampton GM, et al. Diverse EGFR Exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic of NSCLC. J Thorac Oncol. 2018;13(10):1560-1568. 10.1016/j. jtho.2018.06.019.
11. Arcila M, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Molecular Cancer Therapeutics. 2013; Feb; 12(2):220-9.
12. Dersarkissian M, Bhak R, Lin H, et al. P2.01-103 Real-world treatment patterns and survival in non-small cell lung cancer patients with EGFR Exon 20 insertion mutations. J Thorac Oncol. 2019;14(10)(suppl S681). doi:10.1016/j.-jtho.2019.08.1446
13. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR- mutated advanced NSCLC. N Engl J Med. 2020;382(1):41-50. doi:10.1056/NEJMoa1913662
14. Oxnard JR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 Insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.

 
Referencias

10. Riess JW, Gandar DR, Frampton GM, et al. Diverse EGFR Exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic of NSCLC. J Thorac Oncol. 2018;13(10):1560-1568. 10.1016/j. jtho.2018.06.019.
13. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR- mutated advanced NSCLC. N Engl J Med. 2020;382(1):41-50. doi:10.1056/NEJMoa1913662
15. Pennell NA, Mutebi A, Zhou Z, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision analytic model. JCO Precision Oncol. Published online May 16, 2019.
16. Chen D, Song Z, Cheng G. Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. Onco Targets Ther. 2016;9:4181-4186